The expression of the avb3 integrin (CD51/CD61) on human melanoma cells has been shown to be associated most closely with tumor progression and metastases formation in melanoma. Here, we demonstrated a specific interaction of the avb3 integrin on melanoma cells with the human Thy-1, an inducible cell adhesion molecule expressed on the cell surface of activated endothelial cells (EC). The interaction was shown by the binding of purified Thy-1 protein to a V b 3 transfected cells, to avb3-expressing melanoma cells and to purified a V b 3 integrin. Moreover, melanoma cells adhere specifically to Thy-1 transfectants via avb3 on melanoma cells showing the functional relevance of this interaction for cell adhesion. Finally, the importance of the avb3/Thy-1 interaction for the adhesion of melanoma cells to the activated endothelium was confirmed under static and flow conditions by the inhibition of melanoma cell adhesion to and transmigration across activated EC by blocking the avb3/Thy-1 interaction. In conclusion, we have identified a new pair of adhesion molecules Thy-1 and avb3 mediating the interaction of melanoma cells and activated EC. These data explain at least in part the high tumorigenicity of avb3-expressing melanoma cells and the association of avb3-positive melanoma cells with a high risk of metastasis and poor prognosis.
Introduction
Lymphatic and blood vessels provide anatomical 'highways' for the traffic of cancer cells between primary malignant tumors and their distant sites of metastasis. Morphological studies suggest that cancer cells invade into the blood stream mainly via small veins or the sinusoidal neovasculature of their parent tumor (Orr et al., 2000) . This process involves the degradation of the extracellular matrix and of the basement membrane by cancer cell-as well as host cell-derived enzymes (Meyer and Hart, 1998; Wandel et al., 2000 Wandel et al., , 2002 . Many studies document the correlation of metastasis and the expression of matrix-degrading enzymes (Muller et al., 1991; Murray et al., 1996; Chambers and Matrisian, 1997; Yoshizaki et al., 1997) . However, there is general consensus that the arrest of circulating cancer cells is a prerequisite for their emigration from the blood stream and subsequent outgrowth into metastatic tumors. Specific interactions between cancer cells and endothelial cells (ECs) contribute to this process. Cell adhesion molecules of the selectin, integrin, cadherin and immunoglobulin family have been demonstrated to govern these adhesive interactions (Orr et al., 2000) . Several inducible adhesion molecules on ECs (e.g. ICAM-1, VCAM-1, MadCAM-1) have been shown to interact with cancer cells. Additionally, treatment of experimental animals with inflammatory cytokines such as IL-1 or TNF-a prior to injection of tumor cells results in upregulation of inducible adhesion molecules and subsequent increased formation of metastatic tumors (Orosz et al., 1995; Anasagasti et al., 1997) . The mechanisms of tumor cell adhesion to the endothelium and the subsequent invasion into the surrounding tissue share similarities with the interactions occurring during leukocyte extravasation at sites of inflammation. Since the human Thy-1 (CD90) was recently characterized as an activation-associated cell adhesion molecule on ECs with impact on inflammatory process (Wetzel et al., 2004) , we wished to explore the role of this molecule during tumor cell adhesion to activated endothelium.
Thy-1 is a well-known molecule which has been investigated for over three decades. It is familiar to many researchers as a murine T-cell marker. However, Thy-1 shows a remarkable diversity among species (Vidal et al., 1990) : In contrast to mouse, in humans Thy-1 is absent from T-cells and is only expressed by fibroblasts, neuronal cells, blood stem cells and activated microvascular ECs (Williams et al., 1982; Crawford and Barton, 1986; Craig et al., 1993; Saalbach et al., 1999) . In previous investigations we discovered a novel, up-to-now unrecognized function of human Thy-1 serving as an adhesion molecule on activated human ECs Wetzel et al., 2004) . Our recent data prove that Thy-1, expressed on activated human dermal microvascular EC (HDMEC), mediates the binding to neutrophils and monocytes via the interaction with the leukocyte integrin Mac-1 (CD11b/ CD18) (Wetzel et al., 2004) . This demonstrates that human Thy-1 -in addition to ICAM-1 -is an alternative EC receptor for the leukocyte integrin Mac-1, serving an important role for the adhesion and transmigration of neutrophils and monocytes to sites of inflammation.
Based on the findings that (i) Thy-1 is strongly expressed on peri-and intratumoral ECs in melanoma tissues, (ii) an unknown ligand of Thy-1 was detected on melanoma cells (Saalbach et al., 2002) and (iii) melanoma cells adhere to activated Thy-1-expressing ECs (Saalbach et al., 2002) , we sought to identify the binding partner of the Thy-1 on human melanoma cells and to characterize the biological function of this interaction.
In this study, we demonstrate that the specific interaction between human Thy-1 (CD90) on ECs and the integrin avb3 (CD51/CD61) on melanoma cells is of crucial relevance for the adhesion and transmigration of melanoma cells to activated, Thy-1-expressing microvascular ECs.
Results
Human Thy-1 is a counterpart for the integrin avb3 (CD51/CD61)
To identify the avb3 integrin as a Thy-1-ligand, binding of purified, human Thy-1 to avb3-transfected CHO cells was studied. As shown in Figure 1a , purified, biotinylated human Thy-1 binds to avb3-transfected CHOcells, whereas almost no binding to vector-transfected CHO control cells was detectable (Figure 1a) . A biotinylated BSA was used as another negative control to exclude unspecific binding of purified Thy-1 (Figure 1a ). Both the av as well as the b3 chain of the integrin were expressed on the cell surface of all transfected CHO cells, tested by binding of an antibody recognizing only the dimerized avb3 complex (Figure 1b) .
For further evidence, we compared the binding of an anti-CD51-(av) and an anti-CD61-(b3) antibody with the binding of the purified labeled Thy-1-protein to avb3-positive (M21) and a avb3-negative (M21L) variant of the melanoma cell line M21. As shown in Figure 1c , purified Thy-1 and the anti-CD51 and anti-CD61 antibody displayed an identical binding pattern. In contrast, purified Thy-1 bound only faintly to the avb3-negative M21L variant according to the avb3 deficiency of this variant (Figure 1c) .
Since experiments shown in Figure 1 suggested an interaction of Thy-1 and avb3 integrin, the direct interaction between the purified proteins Thy-1 and avb3 was examined in a cell-free system. Indeed, a binding of purified, labeled human Thy-1 to immobilized avb3 could be demonstrated (Figure 2) . Binding of Thy-1 to immobilized BSA was used as blank to determine the specific binding of Thy-1 to avb3. Monoclonal antibodies against the av-chain (anti-CD51) as well as against the b3 chain (anti-CD61) inhibited specifically the binding of Thy-1 to the avb3 aCD61 (β3) aCD61 (β3) purified Thy1 purified Thy1
Figure 1 Thy-1 binds to avb3 (CD51/CD61) expressed on the cell surface of avb3-transfected cells and melanoma cells. Binding of purified, biotinylated human Thy-1 or anti-CD51 and anti-CD61 antibodies was detected by streptavidin-phycoerythrin and goatanti-mouse-Ig-FITC, respectively. Subsequently, cells were analysed by flow cytometry. (a) Purified, biotinylated human Thy-1 binds to the cell surface of avb3 (CD51/CD61) transfected CHO cells (black filled curve), whereas there is almost no binding to vector-transfected CHO cells (gray filled curve) used as control. The thin line represents the binding of biotinylated albumin to avb3-transfected CHO cells used as negative control. The figure represents a typical experiment. (b) Binding of anti-avb3 antibody (LM609) to avb3-transfected CHO cells (gray curve) and the respective isotype control (white curve). (c) Antibodies against CD51, CD61 and purified, biotinylated human Thy-1 bind to the cell surface of M21 melanoma cells (gray filled curve). The selected variant M21L lacking av-expression was not stained by an anti-CD51 antibody. An anti-CD61 antibody as well as the purified Thy-1 bound weakly to the cell surface of the M21L variant (gray filled curve). The thin lines represent the binding of biotinylated albumin as control for labeled Thy-1 and an IgG1 control antibody as control for specific mAb, respectively. The figure represents a typical experiment of four independent experiments
Thy1/avb3 mediates cell-cell adhesion A Saalbach et al integrin up to 40-70%; by contrast, an IgG control antibody had no effect (Figure 2 ).
Adhesion of melanoma cells to human Thy-1 is mediated by the avb3 integrin
To determine whether the Thy-1/avb3 interaction is involved in melanoma cell adhesion to Thy-1-expressing cells, we established a CHO cell line stably transfected with human Thy-1. Full-length Thy-1 was transfected into CHO cells and stable transfectants were isolated. Using flow cytometry, we showed that >90% of stably Thy-1-transfected CHO cells (CHO.Thy-1) expressed Thy-1 on their cell surface, whereas vectortransfected control cells (CHO.vec) did not ( Figure 3 ). CHO-Thy-1-, CHO-vec-cells, the melanoma cell line M21 expressing avb3 and its avb3-deficient variant M21L were used in cell adhesion assays (Figure 1c ). M21 melanoma cells adhered strongly to Thy-1 transfectants consistently with the clear binding of purified Thy-1 to these cells (Figures 4a, 1c) . The avb3-deficient M21L variant bound significantly less to CHO-Thy-1 according to the faint binding of purified Thy-1 to M21L (Figures 4a, 1c ). Moreover, we tested several melanoma cell lines differing in their avb3 expression.
As shown in Figure 4a , melanoma cell lines expressing both the av-as well as the b3-chain of integrins (Mewo, JPC298, P1, A375, M21) adhered clearly to Thy-1-transfected cells, whereas only a weak adhesion to vector-transfected control cells was detectable. In contrast, cell lines expressing only the av-chain (SKMel-28, Bro, HT144) or lacking both chains (M21L) were not able to bind to Thy-1-transfected cells (Figure 4a ). Furthermore, binding of M21 as well as JPC melanoma cells, but not of the avb3-deficient M21L cell line, to Thy-1-transfected CHO cells was significantly inhibited by about 70-80% following preincubation with an antibody against the avb3 heterodimer (clone LM609, Figure 4b ). In fact, such an inhibition of avb3 reduced the adhesion of avb3-positive melanoma cells to the level of melanoma cells lacking avb3 on their cell surface (M21L). As yet another specificity control, incubation with an isotype control antibody as well as antibodies detecting other cell surface antigens, for example, HLA-ABC, or other integrin chains (a3 (CD49c); a5 (CD49e)) did not affect the adhesion to Thy-1-transfected cells (Figure 4b ).
To further examine the binding characteristics of the avb3/Thy-1 interaction, we studied the impact of stimulation of the affinity or avidity of avb3 by preincubation of melanoma cells with Mn 2 þ /Mg 2 þ ions or PMA, respectively. As shown in Figure 4c , divalent cations had no significant effect on the Thy-1/avb3-mediated melanoma cell adhesion. In contrast, PMA clearly stimulated the Thy-1-mediated melanoma cell adhesion (Figure 4c ). Furthermore, an RGD peptide was able to significantly reduce the Thy-1-mediated melanoma cell adhesion (Figure 4c ). Purified Thy-1 protein interacts with pure avb3 integrin and this interaction is inhibited by mAb against the avb3 integrin in a cell-free system. Binding of purified, biotin-labeled Thy-1 to immobilized avb3 integrin or BSA was detected in the absence or presence of mAb to CD51 (av), CD61 (b3), in combination of anti-CD51 and anti-CD61 antibodies and/or IgG control antibody, respectively. The binding of biotinylated Thy-1 was detected by addition of alkaline phosphatase-conjugated streptavidin. Nonspecific binding to BSA-coated wells was used as blank to calculate specific Thy-1-binding. Binding of biotin-labeled Thy-1 to avb3-coated wells in the presence of blocking antibodies against CD51 and CD61 was expressed as % compared to adhesion in the presence of an irrelevant control antibody which was set to 100%. Data are represented as mean7s.d. of three independent experiments measured in duplicate. Thus far, the experiments described above demonstrated a specific interaction of Thy-1 and avb3 on melanoma cells and its functional role in cell adhesion. Next we wished to determine the functional importance of this interaction under more physiological conditions. First, we studied the functional relevance of the avb3/Thy-1 interaction in the adhesion of melanoma cells to HDMEC, the physiological target in vivo that also express the naturally occurring panel of different adhesion molecules.
To block Thy-1, we generated an mAb (B-C9) which is capable of functionally blocking Thy-1-mediated cellcell adhesion. The mAb B-C9 recognized Thy-1-transfected cells as well as Thy-1-expressing fibroblasts, whereas no binding to vector-transfected control cells was detectable (Figure 5a ). Furthermore, we showed that the mAb B-C9 recognizes specifically the Thy-1 protein when immunoprecipitated with the anti-Thy-1-antibody AS02. Conversely, we also demonstrated that the mAb B-C9 precipitates a protein which is recognized by the anti-Thy-1 antibody AS02 ( Figure 5b ). In both experiments, irrelevant control antibodies neither precipitated a protein which is detectable by one of these antibodies nor were able to bind to the precipitated proteins. These results prove that mAb B-C9 recognizes the human Thy-1. Finally, in adhesion assays we illustrated that the mAb B-C9 is able to inhibit the adhesion of melanoma cells to Thy-1-transfected cells to about 60% in comparison to an irrelevant isotype control antibody. Likewise, blocking avb3 with the antiavb3 antibody (LM609) reduced the melanoma cell adhesion to a similar extent. This blocking effect is specific, since both antibodies do not interfere with binding of melanoma cells to control cells in the absence of Thy-1 (CHO.vec; Figure 5c ). The mAb B-C9 was used to investigate the role of the Thy-1/avb3 interaction in melanoma cell adhesion to activated HDMEC. PMA treatment (48 h, 20 ng/ml) results in Thy-1 expression on 40-70% of cultured HDMEC (Saalbach et al., 1999) . Subsequently, melanoma cell adhesion to activated, Thy-1-expressing HDMEC was determined in the presence of functionblocking antibodies to Thy-1 (mAb B-C9) as well as to the avb3 integrin (LM609). As shown in Figure 6 , both blocking of Thy-1 and avb3 results in a significant decrease in melanoma cell adhesion to activated, Thy-1-expressing HDMEC. Inhibition of avb3 reduced the adhesion of avb3-positive M21 melanoma cells to the level of avb3-deficient melanoma cells (M21L) similar to the experiments using Thy-1 transfectants (Figure 4b ). In contrast, the antibodies had no impact on the basal adhesion of melanoma cells to unstimulated HDMEC (data not shown).
Previous studies showed the functional role of Thy-1 in the adhesion of melanoma cells under static conditions. Next, we further evaluate the impact of the avb3/ Thy-1 interaction for melanoma cell adhesion under flow conditions simulating the physiological situation during circulation and invasion of melanoma cells in secondary tissues during metastasis formation.
Melanoma cells were directed over a confluent cell monolayer under a constant flow of 0.15 ml/min (5 dyn/ cm 2 ). As shown in Figure 7a , avb3-positive melanoma cells (JPC) were also able to bind to Thy-1-transfected cells under this conditions (2475 cells/microscopic field), whereas these melanoma cells adhered significantly less to the vector-transfected control cells (1371 cells/microscopic field). Thus, adhesion of avb3-expressing melanoma cells to Thy-1 transfectants is clearly enhanced compared to the control cells under static as well as under flow conditions (Figures 4a, 7) . Thy1/avb3 mediates cell-cell adhesion A Saalbach et al
Next, we were interested in the physiological role of the Thy-1/avb3 interaction in the adhesion of melanoma cells to activated, Thy-1-expressing HDMEC under flow conditions.
As shown in Figure 7b , melanoma cells (JPC) clearly adhered to activated HDMEC under flow conditions (7871 cells/microscopic field). An isotype control antibody had no effect on this adhesion (74714 cells/ microscopic field). Blocking of Thy-1 as well as avb3 significantly inhibited (3172 and 2272 cells/microscopic field, respectively) the adhesion of melanoma cells to activated HDMEC about 60-70% (Figure 7) . Taken together, blocking of Thy-1 or avb3 reduce the adhesion of melanoma cells to activated ECs about 50-70% under static as well as under flow conditions (Figures 6, 7) .
Finally, the role of the Thy-1/avb3 interaction on the transmigration of melanoma cells across a confluent monolayer of PMA-activated, Thy-1-expressing HDMEC was examined. HDMEC were cultured on transwell inserts and Thy-1 expression was induced by PMA. HDMEC were extensively washed to remove PMA before transmigration assay was performed. The functional relevance of Thy-1 and avb3 for transmigration was studied by inhibition of Thy-1 or avb3 by function-blocking antibodies compared to an isotype control antibody. Importantly, the transmigration of melanoma cells (JPC) across a monolayer of activated Thy-1-positive HDMEC was inhibited about 50% by blocking Thy-1 with the mAb BC9 as well as by blocking avb3 on melanoma cells compared to an isotype control antibody (Figure 8) . Thus, the specific Thy1/avb3 mediates cell-cell adhesion A Saalbach et al interaction between Thy-1 and avb3 contributes to both the adhesion and transendothelial migration of melanoma cells.
Discussion
The expression of the avb3 integrin (CD51/CD61) has been shown to be associated most closely with tumor progression and metastasis formation in human malignant melanoma. It is presently the best molecular marker correlating with the change from radial to vertical growth in primary melanoma (Johnson, 1999) . As this change is thought to be a hallmark of the development of a metastatic phenotype, avb3 expression by melanoma cells is a reliable predictor of poor clinical prognosis. Several molecular mechanisms may explain the tumor-promoting activity of avb3. For example, expression of avb3 on ECs (EC) plays a pivotal role in tumor-induced angiogenesis (Varner and Cheresh, 1996; Kumar et al., 2000) . On the other hand, activation of avb3 on melanoma cells prevents apoptosis, stimulates tumor growth and matrix invasion (Johnson, 1999) . Here, we report for the first time that the avb3 integrin on melanoma cells serves a functional role as a cell-cell-adhesion molecule mediating the binding of melanoma cells to the endothelium via the interaction with the human Thy-1 (CD90).
Since the interaction of melanoma cells with the endothelium and subsequent transmigration through the EC barrier is an important prerequisite for tumor cell metastasis, our findings present yet another, previously unrecognized mechanism by which avb3 promotes melanoma progression.
The human Thy-1 is an activation-associated cell adhesion molecule on HDMEC (Saalbach et al., 1998 (Saalbach et al., , 1999 . In situ, the expression of Thy-1 was detected exclusively on EC that show signs of cell activation, inflammation or angiogenesis, including the stromal environment of malignant melanomas (Saalbach et al., 1998 (Saalbach et al., , 1999 (Saalbach et al., , 2002 . In contrast, there was no expression of Thy-1 on the cell surface of resting EC in healthy tissues (Saalbach et al., 1998 (Saalbach et al., , 1999 Wetzel et al., 2004) . Leyton et al. (2001) identified the avb3 on murine astrocytes as a Thy-1 ligand in mice. However, Thy-1 expression in humans and mice shows striking crossspecies differences as described earlier (Saalbach et al., 2002) . Therefore, data describing Thy-1 expression and function cannot be easily transferred between species, and complicate the validation of the physiological importance of the Thy-1/avb3 interaction in in vivo models. Furthermore, the functional relevance of the interaction of murine Thy-1 and avb3 is still unknown. By contrast, in the present study, we identified for the first time the functional role of this interaction for the adhesion of melanoma cells to ECs in humans.
We demonstrated a specific interaction of the human Thy-1 with the avb3 integrin by the binding of purified Thy-1 protein to avb3-transfected cells, to avb3-expressing melanoma cells and to purified avb3 integrin. The specificity of this interaction was demonstrated by the inhibition with antibodies against the av-or b3-chain.
The functional role of this interaction was demonstrated in cell-cell adhesion assays showing a strong and specific adhesion of different avb3-positive melanoma cell lines to Thy-1 transfectants. The inability of melanoma cells lacking the b3-chain to bind to Thy-1-transfected cells as well as the strong inhibition of the Thy-1/avb3 interaction by an anti-b3 antibody point to the importance of the b3-chain for this interaction.
Moreover, blocking avb3 reduced the adhesion of avb3-expressing melanoma cells to the level of melanoma cells lacking avb3. The specificity of the avb3 blockade is also underlined by the fact that other antibodies against several cell surface molecule did not influence the Thy-1-mediated melanoma cell adhesion as well, as that these antibodies did not interfere with the adhesion of avb3-negative melanoma cells. Furthermore, an increase of the avidity of avb3 by PMA also enhanced the Thy-1-mediated melanoma cell adhesion. These results prove that binding of melanoma cells to Thy1 is realized by the interaction with the avb3 integrin on melanoma cells.
Since avb3 interacts with an RGD motif and Thy-1 contains an RLD peptide, a similar sequence, we tested whether RGD peptides are able to interfere with the avb3/Thy-1 interaction. The inhibition of the Thy-1-mediated adhesion of melanoma cells by RGD peptides Thy1/avb3 mediates cell-cell adhesion A Saalbach et al suggest that avb3 could bind to the RLD motif in the Thy-1. Thus, our results also demonstrate that conceivable therapeutic strategies based on the inhibition of avb3 (humanized antibodies, small molecule inhibitors, or RGD-based peptides) would also affect melanoma cell adhesion to Thy-1-expressing cells, including activated ECs or fibroblasts. Finally, the relevance of the avb3/Thy-1 interaction for the adhesion of melanoma cells to ECs was investigated. The significant inhibition (about 50-60%) of the binding of melanoma cells to activated EC by blocking the avb3/Thy-1 interaction demonstrates the importance of this mechanism for melanoma cell adhesion to ECs.
Our findings that also under a constant shear flow (5 dyn/cm 2 ) melanoma cells strongly adhere to Thy-1 transfectants and that melanoma cell adhesion to activated, Thy-1-expressing ECs is significantly inhibited by blocking the avb3/Thy-1 interaction underlines the importance of this interaction for the attachment of melanoma cells to ECs as a prerequisite for their transmigration into the tissue. Moreover, the Thy-1/ avb3 interaction is also involved in the transmigration of melanoma cells since blocking Thy-1 and avb3 resulted in a significant inhibition of the migration of melanoma cells across a monolayer of activated, Thy-1-expressing ECs. Taken together, our data provide strong evidence that Thy-1 expressed on ECs is involved in the adhesion and transmigration of melanoma cells via the interaction with avb3 integrin, thereby promoting the invasion of melanoma cells into secondary tissues and subsequent metastasis formation. In accordance, avb3-expressing melanoma cells exhibit a high tumorigenicity in mice. In contrast, a melanoma cell line (M21L) lacking avb3 expression showed a dramatically reduced tumorigenicity when transplanted into nude mice (Cheresh and Spiro, 1987; Felding-Habermann et al., 1992) .
Until now, the best known ligands of the avb3 integrin are matrix proteins such as vitronectin, fibronectin, laminin, collagen and osteopontin (Smith and Cheresh, 1990; Felding-Habermann and Cheresh, 1993; Byzova et al., 2000) . In this respect, our finding that Thy-1 and avb3 interact is important since it demonstrates that the avb3 does not only interact with matrix components but also with a cell surface receptor on EC resulting in cell-cell adhesion. The identification of the Thy-1 on activated EC as a avb3 ligand is in good accordance with data showing that the integrin avb3 recognizes the human neuronal cell adhesion molecule L1 and platelet EC adhesion molecule-1 expressed on EC (Buckley et al., 1996; Ebeling et al., 1996; FeldingHabermann et al., 1997) . Both interactions were assumed to be involved in leukocyte extravasation to sites of inflammation, tissue injury or infection (Piali et al., 1995; Duczmal et al., 1997; Weerasinghe et al., 1998) . Voura et al. (2001) also demonstrated the involvement of the avb3 interaction with L1 in the transmigration of melanoma cells. Thus, avb3 integrin mediates both cell adhesion to extracellular matrix as well as cell-cell adhesion.
In conclusion, we have identified a new pair of adhesion molecules Thy-1 and avb3 mediating the interaction of melanoma cells and activated EC. These data explain at least in part the high tumorigenicity of avb3-expressing melanoma cells and the association of avb3-positive melanoma cells with a high risk of metastasis and poor prognosis.
Materials and methods

Monoclonal antibodies (mAb)
The mAbs against the avb3 integrin and the IgG1 isotype control were purchased from Chemicon (anti-CD51, anti-avb3 (clone LM609), Hofheim, Germany) and Immunotech (anti-CD61 Hamburg, Deutschland). Phycoerythrin (PE)-and CYt3-labeled streptavidin, dichlorotriazinyl-amino-fluorescein (DTAF)-labeled goat-anti-mouse were purchased from Jackson Immunoresearch (USA). Monoclonal antibody AS02 (anti-Thy1) was used as hybridoma cell culture supernatant as described previously (Saalbach et al., 1998) . The RGD peptide (GRGDSPK ) was purchased from Sigma (Deisenhofen, Germany).
Cell lines and culture conditions
The melanoma cell lines JPC 298 (Aubert et al., 1993) , A375 (Giard et al., 1973) , Mewo (Bean, 1975) , P1 (kindly provided by Dr Dummer, Zurich), SK-Mel28 (Carey et al., 1976) , HT144 (Ahrens et al., 2001) , Bro (Lockshin et al., 1985) were maintained in RPMI 1640 with stable glutamine supplemented with penicillin (400 U/ml), streptomycin (50 mg/ml), ascorbic acid (50 mg/ml) and 10% fetal calf serum (Seromed s , Biochrom KG; Berlin, Germany), in a humidified atmosphere of 5% CO 2 at 371C.
The M21 melanoma cell line and its stable variant lacking the av integrin (M21L) were kindly provided by Dr D Cheresh (The Scripps Institute, La Jolla, CA, USA) and cultured in DMEM with 10% FCS and 1% penicillin/streptomycin at 371C, 5% CO 2 . The M21 cell line was passaged after reaching confluence using 0.05% trypsin, 0.02% EDTA, whereas M21L grows in suspension.
The avb3-, vector-transfected CHO cells and CHO cells were kindly provided by Professor Gawaz (Herzzentrum Munich, Germany). Cells were cultured in DMEM with 10% FCS and 1% penicillin/streptomycin at 371C, 5% CO 2 , and passaged after reaching confluence using 0.05% trypsin, 0.02% EDTA.
HDMEC were prepared from human foreskin. The epidermis was removed after 24 h incubation with dispase (2.5 mg/ml; Roche Applied Science, Mannheim, Germany). The dermis was firmly pressed with a scalpel to release ECs. The EGM-MV Bulletkit (Promocell, Heidelberg, Germany) was used for culture according to the original protocol.
To assess the quality of cell preparation (contamination with fibroblasts), CD31 expression (anti-CD31, BeckmannCoulter, Krefeld, Germany) was tested by flow cytometry as described (Saalbach et al., 2002) . Only preparations with >90% CD31-positive cells were used. To induce Thy-1 expression, HDMEC were stimulated with 20 ng/ml phorbolester (PMA) for 24 h (phorbol myristate acetate; Invitrogen, Carlsbad, CA, USA).
Generation of stably Thy-1-transfected CHO cells
Full-length Thy-1 cDNA (accession number: M11749) from base 27-1519 resulting in the complete mature protein was Thy1/avb3 mediates cell-cell adhesion A Saalbach et al cloned into pcDNA6 vector containing a blasticidin resistance gene (Invitrogen). CHO cells were detached using 0.05% trypsin, 0.02% EDTA and transfected with 1 mg plasmid containing Thy-1 or with the vector alone by electroporation (300 V, 1500 mF; Equibio (Peqlab, Erlangen, Germany)). Cells were immediately transferred into cell culture and blasticidin (7.5 mg/ml, Invitrogen) was added after 48 h to select stably transfected cells. Transfectants expressing Thy-1 were identified by flow cytometry using an anti-Thy-1-antibody (mAb AS02; Saalbach et al., 1998) .
Generation of an anti-Thy-1-antibody blocking Thy-1-dependent cell adhesion Balb/c mice were immunized intraperitoneally with 1 Â 10 7 cells of Thy-1-transfected CHO cells (Thy-1-CHO) 9 and 3 weeks before booster immunization. Spleen cells were fused with X63-Ag.8.653 myeloma cells using polyethyleneglycol according to the principle of Ko¨hler and Milstein (1975) . Hybridoma supernatants were screened for antibodies that bind to Thy-1-CHO but do not recognize vector-transfected CHO cells. One hybridoma clone of interest (patent pending) was selected, recloned and used as hybridoma cell culture supernatant in subsequent investigations.
Protein purification of human Thy-1
Thy-1 was purified from cell extracts of human dermal fibroblasts by immunoaffinity-chromatography using mAb AS02 as described previously (Saalbach et al., 1998) .
Briefly, the Thy-1-specific mAb AS02 was immobilized on cyanogen bromide-activated sepharose (AmershamBiosciences, Freiburg, Germany) according to the manufacturer's protocol. Human dermal fibroblasts were solubilized in 20 mM phosphate buffer with 0.5% Triton X-100, 1 mM phenylmethylsulfonyl-fluoride, 25 mM EDTA, 10 mg/ml leupeptin and aprotinin for 30 min and were cleared by centrifugation at 10 000 g; 10 min at 41C. The resulting supernatant was incubated with the cyanogen bromide-activated sepharose coupled with mAb AS02 in batch overnight at 41C. After extensive washing with PBS, the bound proteins were eluted with 0.2 M triethylamine, pH 11.5 and neutralized with 10 mM phosphate buffer, pH 6.0. The eluted fractions containing purified Thy-1 were pooled and concentrated by ultrafiltration (Amicon, Witten, Germany). Subsequently, purified Thy-1 was labeled with D-biotinoyl-e-aminocaproic acid-hydroxysuccinimide ester (Roche Biochemicals, Mannheim, Germany) according to the manufacturer's protocol.
Flow cytometry analysis
Adherent cells were harvested and washed twice in PBS and about 2 Â 10 5 cells were pelleted in 96-well plates. Subsequently, cells were incubated with 1 mg of the respective mAbs (mAb against CD51, CD61, Thy-1 or IgG1 isotype control). After washing twice with PBS/Gelafusal (Serumwerke Bernburg, Germany), cells were incubated with DTAFlabeled goat-anti-mouse secondary antibody (diluted 1 : 200 in PBS).
Alternatively, cells were incubated with biotinylated purified Thy-1 or biotinylated bovine serum albumin (BSA) as negative control for 60 min at 41C following PE-labeled streptavidin (1 : 100 in PBS).
Finally, cells were washed twice with PBS, and antibody or Thy-1 binding to cells was analysed by flow cytometry (Epics XL, Beckman Coulter, Krefeld, Germany).
Immunoprecipitation
The anti-Thy-1 mAb as well as an isotype control IgG antibody (10 mg) were bound to 1 Â 10 8 goat-anti-mouse IgG-DYNABEADSR M450 (Dynal/ Oslo, Norway) overnight at 41C, respectively. After washing with PBS, these beads were incubated with crude extracts of 5 Â 10 6 fibroblasts for 16 h at 41C. Proteins bound to magnetic beads were eluted with SDSloading buffer after extensive washing with PBS/0.3% Tween 20. The isolated proteins were separated by SDS-PAGE and blotted onto nitrocellulose membranes. The anti-Thy-1 mAbs or an isotype control IgG antibody followed by a secondary goat-anti-mouse antibody conjugated with alkaline phosphatase were used to detect the isolated proteins as described previously (Saalbach et al., 1996) .
In vitro ligand-receptor interactions
MaxiSorb plates (Nunc, Wiesbaden, Germany) were coated with 200 ng/well avb3 integrin (Chemicon) or BSA in TBS 2 mM CaCl 2 /0.1 mM MgCl 2 overnight. Plates were washed three times with TBS and blocked with TBS/1% BSA for 30 min at room temperature. Purified, biotinylated Thy-1 (1 mg/well) was added to immobilized avb3 as well as to BSAcoated control wells. Plates were washed with TBS containing 0.1% BSA, 0.05% Tween-20, 2 mM CaCl 2 and 0.1 mM MgCl 2 after 2 h at room temperature. Thy-1 binding to immobilized avb3 as well as to BSA as negative control was performed in the absence or presence of mAb to CD51, CD61 (10 mg/ml), respectively. The binding of biotinylated Thy-1 was detected by addition of alkaline phosphatase-conjugated streptavidin (Sigma). Subsequently, para-nitrophenyl-phosphate (pNPP, 1 mg/ml) was used to generate color reaction that was measured at 405 nm. Nonspecific binding to BSA-coated wells was used as blank to calculate specific Thy-1-binding.
Static cell adhesion assays
Cell adhesion to Thy-1-expressing cells Vector-transfected CHO cells, Thy-1 transfected CHO cells or stimulated HDMEC were seeded on chamber slides (NUNC, Wiesbaden, Germany) and cultured for 24 h to obtain a confluent cell monolayer. Melanoma cells were biotinylated with D-biotinoyl-e-aminocaproic-acid-hydroxysuccinimide-ester (Roche Biochemicals, Mannheim, Germany) according to the manufacturer's protocol, and 5 Â 10 5 of the respective cells were added to each well of chamber slides. After incubation for 30 min at 371C, unbound cells were removed by several washes with PBS. Adherent cells were fixed with ice-cold methanol for 10 min at À201C, air-dried and blocked by incubation with PBS/1% BSA. Subsequently, adherent biotinylated cells were visualized by incubation with CYt3-conjugated streptavidin (Beckman Coulter, 1 : 500 in PBS/1% BSA) for 30 min at room temperature and finally washed twice with PBS. In blocking experiments, cells were preincubated with mAb against CD51, CD61, Thy-1 or with IgG1 as control for 30 min, and, subsequently the adhesion assay was performed as described above. The number of adherent cells was counted in 10 microscopic fields.
Cell adhesion assays under flow conditions
To detect melanoma cell adhesion under flow conditions, CHO.Thy-1, CHO.vec or PMA-stimulated HDMEC were cultured on glass coverslips coated with 0.1% gelatine. The adherent cells were maintained in RPMI 1640 medium without serum in a heated incubation chamber (PTS GmbH, Germany) at 371C. Melanoma cells were labeled for 30 min at 371C in Thy1/avb3 mediates cell-cell adhesion A Saalbach et al RPMI 1640 without serum containing 1 mM FURA2/AM (1-(2-(5-carboxyoxoazol-2-yl)-6-aminobenzofuran-5-oxy)-2-(2 0 -amino-5 0 -methylphenoxy)-ethane-N,N,NX 0 ,N 0 ,-tetraacetate, pentaacetoxymethyl-ester, Molecular Probes, USA), washed twice and resuspended in RPMI 1640 without serum (2 Â 10 5 cells/ ml). Labeled melanoma cells were directed over the confluent cell monolayer of CHO.Thy-1, CHO.vec or stimulated HDMEC in a flow chamber under a constant flow of 0.15 ml/min (5 dyn/cm 2 ) for 2 min. The monolayer was washed with RMPI 1640 for 3 min under the same flow conditions to remove unbound cells. Finally, adherent cells were counted in 20 microscopic fields ( Â 20 magnification) and representative images were recorded using a TILLPhotonics digital video imaging system consisting of a TILL-imago CCD camera and a Polychrome II monochromator (TILL-Photonics, Germany) connected to a IX-71 inverted microscope (Olympus, Germany) as described previously by Averbeck et al. (2004) . The Fura-labeled melanoma cells were recorded at 340 nm/ 380 nm excitation and 510 nm emission as well as the confluent cell monolayer was detected in transmission images (800 nm). Three independent experiments were performed.
Transendothelial migration assay
HDMEC were seeded into transwell culture inserts (pore size 8 mm; Falcont, BD biosciences, Heidelberg, Germany). After reaching a confluent cell monolayer, cells were stimulated with PMA (20 ng/ml) for 24 h to induce Thy-1 expression. To block Thy-1, cells were incubated with the function-blocking antiThy-1-antibody BC9 or with an isotype control antibody for 30 min at 371C. For blocking avb3 on melanoma cells, these cells were incubated with a function-blocking antibody against the dimer of avb3 (LM609). Melanoma cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFDA; Molecular Probes) according to the manufacturer's protocol. After extensive washing of the HDMEC monolayer, a melanoma cell suspension (2 Â 10 5 in 500 ml RPMI without serum) was given to the upper compartment of the transwell culture inserts, whereas 500 ml RPMI/10% FCS was given to the lower compartment as chemoattractance. The transmigration was performed for 16 h at 371C, 5% CO 2 . Subsequently, the transwell culture inserts were removed, cells migrated into the lower compartment were resuspended and fluorescein-labeled cells were counted by flow cytometry.
Statistical analysis
Statistical analysis was performed using the Wilcoxon t-test; P-values of o0.05 were regarded as significant.
